Table 1.

Comparison of baseline characteristics between the development and validation cohorts.

Variable	Development set (n=103)	Validation set (n=44)	Statistics value	P value
BMI	23.47 ± 4.44	23.80 ± 3.72	-0.47	0.64
Age	70.41 ± 8.26	69.93 ± 9.36	0.29	0.77
Gleason score			0.12	0.73
≤8	61 (59.22%)	24 (54.55%)
>8	42 (40.78%)	20 (45.45%)
Treatment			0.02	0.90
ADT+ARPI	52 (50.49%)	21 (47.73%)
ADT+ARPI+Docetaxel	51 (49.51%)	23 (52.27%)
Lymph node metastasis	49 (47.57%)	15 (34.09%)	1.76	0.18
ECOG PS			0.47	0.49
<2	43 (41.75%)	15 (34.09%)
2	60 (58.25%)	29 (65.91%)
Total PSA	47.014 ± 65.651	41.166 ± 49.736	0.591	0.556
Bone metastasis burden			1.554	0.213
<3 sites	69 (67.0%)	24 (54.5%)
≥ 3 sites	20 (45.5%)	20 (45.5%)	1.554	0.213
Measurable visceral metastasis	36 (35.0%)	21 (47.7%)	0.616	0.204
LDH	210.442 ± 47.731	210.570 ± 40.781	-0.017	0.987
ALP	91.858 ± 28.230	91.918 ± 24.042	-0.013	0.99
Hb	123.755 ± 13.111	124.182 ± 12.332	-0.188	0.851